ONCOLOGY Vol 38, Issue 11

Personalized therapy for non–small cell lung cancer has evolved significantly with the advent of comprehensive molecular testing.

Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.

DLBCL is a genetically heterogeneous malignancy with multiple subtypes and recent investigations based on molecular profiles have opened the possibility for personalized therapy in this disease space.

This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.

The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.

Julie M. Vose, MD, MBA, highlights the push toward gender diversity in medical oncology.

A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.

Thomas G. Martin, MD, discussed the advantages of quadruplet therapy for multiple myeloma in light of an FDA approval for Isa-VRd in this indication.

A nurse practitioner discussed how her role plays a vital part in patient care for those undergoing talquetamab treatment for multiple myeloma.